Prostate cancer survivor

grandfather and grandson playing guitar

Why Myriad germline testing?
Because every man and his family deserve better answers

We understand that the decision to pursue definitive treatment for you or your loved one’s prostate cancer wasn’t easy. That’s why at Myriad, we offer a suite of personalized genetic testing solutions that can provide you and your healthcare provider with peace of mind regardless of where you’re at in the treatment journey.

Learn more about how genetics impact treatment decisions

Myriad Prostate Cancer testing options

Genetic testing could save your family’s life

As you learn to navigate life after treatment, it’s important to understand that cancer doesn’t have an on/off switch. Up to 1 in 6¹ men with prostate cancer have a genetic mutation that may have caused their cancer. Germline hereditary cancer or genetic testing is the only way to identify this risk and your personalized results can directly impact current and future treatment decisions. Your results can also provide your family with peace of mind by informing them of their risk of developing hereditary cancers in the future.


6× more likely
to die from prostate cancer


If you have a mutation, your sons and daughters have a 50% chance of also having a mutation


4× more likely
to develop metastasis

Have additional questions?

Speak with a Patient Advocate now 1-855-469-7765

Which test is right for me?

Myriad offers personalized testing options so that you can better understand your individual cancer risk and customize your treatment journey.

MyRisk Hereditary Cancer Treatment logo

Hereditary Cancer Panel Testing:

Myriad myRisk® test is a 35-gene cancer panel that will provide patients with prostate cancer comprehensive information about your unique cancer. Using industry leading accuracy, unmatched turnaround time, and a lifetime commitment to patients, myRisk is an essential part of prostate cancer evaluations.

BRACAnalysis CDx Companion Diagnostic Test logo

BRCA Testing – To Help Determine which Patients may be Appropriate for PARP Inhibitor Therapy

CDx can help determine if you might be an appropriate candidate for PARP inhibitor therapy by identifying if you have a germline BRCA 1/2 mutation. The test was designed and FDA approved to provide BRCA 1/2 results quickly and accurately.

grandfather and grandaughter

Genetic testing is easy and affordable

coin icon

97% of private insurances have coverage for testing

group icon

Medicare patients pay $0

Remote testing options are available so you can test directly from home

Submit the form below to receive your testing kit

*You can request your own genetics test kit, but for the test to be covered under insurance, it needs to be ordered by a health care provider.



Prevalence of Germline Variants in Prostate Cancer and Implications for Current Genetic Testing Guidelines Nicolosi et al. JAMA Oncol 2019